SRPT Soars On Q2 Results & Outlook, AERI's Mercury-1 Does An Encore, ALIM Abuzz

Today's Daily Dose brings you news about Aerie Pharma's Mercury-1 study results; reduction in size of Alimera's post-marketing study of ILUVIEN; ContraFect's stock offering; spin-off of Immune Pharma's subsidiary; Sarepta's stellar Q2 results and Theravance's COPD trial results.

from RTT - Biotech http://ift.tt/2vlLCXK
via IFTTT